In Vitro Culturing and Screening of Candida albicans Biofilms
Megha Gulati, Matthew B. Lohse, Craig L. Ennis, Ruth E. Gonzalez, Austin M. Perry, Priyanka Bapat, Ashley Valle Arevalo, Diana L. Rodriguez, Clarissa J. Nobile
下载PDF
{"title":"In Vitro Culturing and Screening of Candida albicans Biofilms","authors":"Megha Gulati, Matthew B. Lohse, Craig L. Ennis, Ruth E. Gonzalez, Austin M. Perry, Priyanka Bapat, Ashley Valle Arevalo, Diana L. Rodriguez, Clarissa J. Nobile","doi":"10.1002/cpmc.60","DOIUrl":null,"url":null,"abstract":"<p><i>Candida albicans</i> is a normal member of the human microbiota that asymptomatically colonizes healthy individuals, however it is also an opportunistic pathogen that can cause severe infections, especially in immunocompromised individuals. The medical impact of <i>C. albicans</i> depends, in part, on its ability to form biofilms, communities of adhered cells encased in an extracellular matrix. Biofilms can form on both biotic and abiotic surfaces, such as tissues and implanted medical devices. Once formed, biofilms are highly resistant to antifungal agents and the host immune system, and can act as a protected reservoir to seed disseminated infections. Here, we present several <i>in vitro</i> biofilm protocols, including protocols that are optimized for high-throughput screening of mutant libraries and antifungal compounds. We also present protocols to examine specific stages of biofilm development and protocols to evaluate interspecies biofilms that <i>C. albicans</i> forms with interacting microbial partners. © 2018 by John Wiley & Sons, Inc.</p>","PeriodicalId":39967,"journal":{"name":"Current Protocols in Microbiology","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpmc.60","citationCount":"61","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpmc.60","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 61
引用
批量引用
Abstract
Candida albicans is a normal member of the human microbiota that asymptomatically colonizes healthy individuals, however it is also an opportunistic pathogen that can cause severe infections, especially in immunocompromised individuals. The medical impact of C. albicans depends, in part, on its ability to form biofilms, communities of adhered cells encased in an extracellular matrix. Biofilms can form on both biotic and abiotic surfaces, such as tissues and implanted medical devices. Once formed, biofilms are highly resistant to antifungal agents and the host immune system, and can act as a protected reservoir to seed disseminated infections. Here, we present several in vitro biofilm protocols, including protocols that are optimized for high-throughput screening of mutant libraries and antifungal compounds. We also present protocols to examine specific stages of biofilm development and protocols to evaluate interspecies biofilms that C. albicans forms with interacting microbial partners. © 2018 by John Wiley & Sons, Inc.
白色念珠菌生物膜的体外培养与筛选
白色念珠菌是人类微生物群的正常成员,在健康个体中无症状地定殖,但它也是一种机会性病原体,可引起严重感染,特别是在免疫功能低下的个体中。白色念珠菌的医学影响部分取决于其形成生物膜的能力,即包裹在细胞外基质中的粘附细胞群落。生物膜可以在生物和非生物表面形成,例如组织和植入的医疗设备。一旦形成,生物膜对抗真菌药物和宿主免疫系统具有高度的抵抗力,并且可以作为种子播散性感染的保护库。在这里,我们提出了几种体外生物膜方案,包括针对突变文库和抗真菌化合物的高通量筛选进行优化的方案。我们还提出了检查生物膜发展的特定阶段的方案和评估白色念珠菌与相互作用的微生物伙伴形成的种间生物膜的方案。©2018 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。